<DOC>
	<DOCNO>NCT02255513</DOCNO>
	<brief_summary>This study examine efficacy safety HLD200 ( methylphenidate ) patient age 6-12 year ADHD . This study 6-week dose optimization period follow one week double blind randomization assessment .</brief_summary>
	<brief_title>A Trial Evaluating Efficacy Safety HLD200 Children With ADHD</brief_title>
	<detailed_description>Attention-Deficit Hyperactivity Disorder ( ADHD ) one common childhood disorder continue adolescence adulthood . Symptoms include difficulty stay focus pay attention , difficulty control behavior hyperactivity ( over-activity ) . This multicenter study utilize 6-week open label , treatment optimization phase follow double-blind , placebo-controlled , 1-week randomize , parallel-group test period design assess safety efficacy HLD200 treatment pediatric subject ADHD .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Male female child ( 612 year study entry ) Previous diagnosis ADHD confirmation use Mini International Neuropsychiatric Interview Children Adolescents ( MINIKID ) Able swallow treatment capsule Available entire study period Provision inform consent ( parent [ ] and/or legal representative [ ] ) assent ( subject ) Female subject childbearing potential ( i.e. , postmenarche ) require negative result urine pregnancy test ( give specific instruction avoid pregnancy trial ) . Any known history presence significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , ophthalmologic disease Presence significant physical organ abnormality Any illness 4 week study Comorbid psychiatric diagnosis may affect subject safety confound result ( e.g. , psychosis , bipolar disorder ) Known history severe asthma ( opinion investigator ) unless deem currently control Known history severe allergic reaction MPH Known history seizure ( except febrile seizure prior age 5 ) , anorexia nervosa , bulimia current diagnosis family history Tourette 's disorder Subject severely underweight overweight ( opinion Investigator ) Any clinical laboratory value outside acceptable range , unless deem NCS significant per Investigator Positive history hepatitis B , hepatitis C Human Immunodeficiency Virus ( HIV ) Positive screen illicit drug use , and/or current health condition use medication might confound result study increase risk subject Use prescription medication ( except ADHD medication ) within 7 day overthecounter medication ( except birth control ) within 3 day precede study enrollment , unless deem acceptable Investigator Clinical Medical Monitor Participation clinical trial investigational drug within 30 day precede study enrollment Current suicidal ideation history suicidality determine significant find CSSRS investigator ( Baseline CSSRS adolescent ; Pediatric Baseline CSSRS child ) .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>